The Trump administration on Tuesday temporarily reinstated dozens of fired federal workers who help screen coal miners for black lung, a deadly and incurable disease caused by inhaling toxic coal ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Chinese Super League All competitions All competitions All competitions ...

The Minnesota Vikings selected Maryland WR Tai Felton with the No. 102 overall pick in the 2025 NFL draft. Tai Felton is a plus-level route runner with good timing to hit his landmarks.

Randy Brown's madness in Kansas City UFC. Ian Garry beats Carlos Prates and ends 'Fighting Nerds' unbeaten run in the UFC Tai Tuivasa (15-8) is not having the best time. The Australian fighter has ...

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear. Scientists at the University of Cambridge, led by Professor Ljiljana Fruk ...

Apr. 22, 2025 — Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Maryland wide receiver Tai Felton runs a drill at the NFL football scouting combine in Indianapolis, Saturday, March 1, 2025. (AP Photo/Michael Conroy) In a small trade shortly before they were ...

Sun Yuan and Peng Yu are a duo of contemporary Chinese artists whose collaborative works intend to elicit strong emotional and physical reactions in the viewer. Employing robotic apparatuses, live ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

advanced PD-L1-positive non-small cell lung cancer (NSCLC). "We evaluate our clinical programmes to focus our resources on the most promising clinically differentiated candidates while ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...